You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT
SBC: ARGOLYN BIOSCIENCE, INC. Topic: N/AArgolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-natural amino acid analogues for arginine (Arg) or lysine (Lys). In proof-of concept studies thus far, application of the Argolyn technology to peptides of therapeutic interest has resulted in dramatic ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS
SBC: ARGOLYN BIOSCIENCE, INC. Topic: N/ADESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrier therefore have significant potential for development as a new class of non-dopamineric antipsychotics expected not to display the adverse side effects associated with the dopaminergics. The best lit ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
DETECTION OF PRION PROTEIN IN BLOOD
SBC: SERACARE LIFE SCIENCES, INC. Topic: N/APrion diseases are 100 percent fatal, there is no treatment available, and cannot be diagnosed prior to the occurrence of symptoms. There is a public health need and an enormous market for a screening test that can help protect the blood supply, screen live animals, and ensure food safety. We propose to develop and validate an innovative, highly sensitive screening method for the detection of the ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
NOVEL DOXORUBICIN ANALOGS:CARDIAC AND CYTOTOXIC EFFECTS
SBC: GEM Pharmaceuticals Topic: N/AAnthracyclines such as doxorubicin and daunorubicin are valuable anti- cancer drugs but their clinical utility is compromised by cumulative dose-dependent by a cumulative dose dependent cardiotoxicity. Anthracycline cardiotoxicity has been linked to free radical damage via mechanisms that involve disruption of iron regulation and formation of superoxide anion. Although the quinone moiety of anthra ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
ENHANCED THERMAL TRANSFER DEVICE FOR BIOPRESERVATION
SBC: ORGAN RECOVERY SYSTEMS, INC. Topic: N/AEffective methods of preserving cells and tissues are essential for the established and emerging companies using cryopreservation as part of their production processes. Conventional freezing and thawing devices have low heat transfer efficiencies that cause non-uniform thermal processing in biological materials resulting in products with low and inconsistent cell viability. The development of an a ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
POLYMERIC DELIVERY OF ENZYMES AND PRODRUGS FOR CANCER
SBC: SHEARWATER POLYMERS, INC. Topic: N/AA clinically promising prodrug for cancer chemotherapy is irinotecan or 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11)which is converted to the active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) in the presence of carboxylesterases (CE). SN-38 inhibits topoisomerase I, causes DNA damage and induces apoptosis. A limiting factor for the effective use of CPT-11 in pa ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
SKIN-PATCH VACCINATION AGAINST ALZHEIMER'S DISEASE
SBC: VAXIN INC. Topic: N/AAlzheimer's disease (AD) and inclusion body myositis (IBM) share a number of common pathologies such as deposits of amyloid beta-protein (AB) and paired helical filaments, although such pathologies are mostly restricted to brain for AD and to muscle for IBM. Transgenic mice (Tg 13592) that express the 99-amino acid carboxyl-terminal fragment (C99) of AB precursor in the brain and skeletal muscle d ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
IMMUNO-ENHANCEMENT OF SKIN PATCH ANTHRAX VACCINATION
SBC: VAXIN INC. Topic: N/ADESCRIPTION (provided by applicant): In the wake of bio-terrorism, anthrax has become a real concern for public. Anthrax is listed as a category A biological disease by the CDC. Inhalation of anthrax spores can result in death due to rapid fatal hemorrhage. Since anthrax aerosol is odorless, invisible and easily spread, the most effective way to protect people from infection is vaccination. S ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
INEXPENSIVE INTERACTIVE MOLECULAR MODELING SOFTWARE
SBC: VERACHEM LLC Topic: N/AToday, promising new protein targets for small molecule drugs are being discovered rapid. With increasing frequency, the 3D structures of these proteins are available or can be modeled from known protein structures. Demand is therefor growing for software to support structure-based discovery of protein ligands as candidate drugs. However, existing software leaves enormous room for improvement in a ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
Development of VPL Vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDProject Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health